Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 985,857
  • Shares Outstanding, K 44,428
  • Annual Sales, $ 90,240 K
  • Annual Income, $ -263,490 K
  • 60-Month Beta 1.27
  • Price/Sales 10.76
  • Price/Cash Flow N/A
  • Price/Book 3.08
Trade RGNX with:

Options Overview Details

View History
  • Implied Volatility 65.12% ( -3.90%)
  • Historical Volatility 104.82%
  • IV Percentile 23%
  • IV Rank 21.26%
  • IV High 118.28% on 02/02/24
  • IV Low 50.77% on 11/17/23
  • Put/Call Vol Ratio 0.33
  • Today's Volume 84
  • Volume Avg (30-Day) 270
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 2,394
  • Open Int (30-Day) 3,063

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.28
  • Number of Estimates 5
  • High Estimate -1.11
  • Low Estimate -1.50
  • Prior Year -1.53
  • Growth Rate Est. (year over year) +16.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.12 +30.43%
on 02/29/24
28.80 -22.47%
on 03/05/24
+3.50 (+18.59%)
since 02/16/24
3-Month
11.83 +88.76%
on 02/02/24
28.80 -22.47%
on 03/05/24
+2.82 (+14.45%)
since 12/18/23
52-Week
11.83 +88.76%
on 02/02/24
28.80 -22.47%
on 03/05/24
+2.20 (+10.93%)
since 03/17/23

Most Recent Stories

More News
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?

The threat is still emerging, but it could be significant.

SRPT : 123.97 (+0.75%)
RGNX : 22.33 (+0.63%)
Regenxbio: Q4 Earnings Snapshot

Regenxbio: Q4 Earnings Snapshot

RGNX : 22.33 (+0.63%)
Regenxbio: Q3 Earnings Snapshot

Regenxbio: Q3 Earnings Snapshot

RGNX : 22.33 (+0.63%)
REGENXBIO to Participate in the Jefferies CNS/Neuro Summit

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Jefferies CNS/Neuro Summit on Thursday, October 12, 2023. Jefferies...

RGNX : 22.33 (+0.63%)
REGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNEâ„¢ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society

RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne that includes an optimized transgene for a novel microdystrophin, continues to be...

RGNX : 22.33 (+0.63%)
REGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the 28th Annual Congress of the World Muscle Society, taking place in...

RGNX : 22.33 (+0.63%)
REGENXBIO to Participate in Upcoming Investor Conferences

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following upcoming investor conferences: Morgan Stanley 21st Annual...

RGNX : 22.33 (+0.63%)
Initial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that initial interim data from a first-in-human single-patient, investigator-initiated trial of...

RGNX : 22.33 (+0.63%)
REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023

/PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023...

RGNX : 22.33 (+0.63%)
Regenxbio: Q2 Earnings Snapshot

Regenxbio: Q2 Earnings Snapshot

RGNX : 22.33 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 24.23
2nd Resistance Point 23.42
1st Resistance Point 22.88
Last Price 22.33
1st Support Level 21.52
2nd Support Level 20.70
3rd Support Level 20.16

See More

52-Week High 28.80
Last Price 22.33
Fibonacci 61.8% 22.32
Fibonacci 50% 20.31
Fibonacci 38.2% 18.31
52-Week Low 11.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar